Brief: ArgenX: Phase 2 Data Establish Proof-Of-Concept Of Efgartigimod
20/11/2024 06:20
Nov 20 (Reuters) - argenx SE ARGX.BR :
* ARGENX ADVANCES CLINICAL DEVELOPMENT OF EFGARTIGIMOD SC IN
IDIOPATHIC INFLAMMATORY MYOPATHIES
* PHASE 2 DATA ESTABLISH PROOF-OF-CONCEPT OF EFGARTIGIMOD SC
IN
MYOSITIS
* ENROLLMENT TO CONTINUE IN PHASE 3 ACROSS ALL THREE
SUBTYPES
* ALKIVIA STUDY TO ENROLL 240 PATIENTS IN TWO PHASES
Source text: ID:nGNE5wZbnf
Further company coverage: ARGX.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles